Citizens Jmp Reaffirms Market Outperform Rating for Immix Biopharma (NASDAQ:IMMX)

Key Points

• Citizens Jmp reaffirmed a Market Outperform rating on Immix Biopharma with a $23.00 price target, implying roughly a 156% upside from the current share price.
• Analyst coverage is mixed but tilted positive — four Buy, one Hold and one Sell — giving a MarketBeat consensus of "Moderate Buy" with a consensus target of $18.00; IMMX opened at $8.98 and has a market cap of about $475.6M.
• Immix is a clinical-stage immuno-oncology company focused on myeloid checkpoint therapies, with lead candidate IMX-110 designed to activate macrophages and dendritic cells in the tumor microenvironment.

Immix Biopharma (NASDAQ:IMMX - Get Free Report)'s stock had its "market outperform" rating reissued by investment analysts at Citizens Jmp in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $23.00 price target on the stock. Citizens Jmp's price target suggests a potential upside of 156.12% from the company's current price.

IMMX has been the subject of several other research reports. HC Wainwright increased their target price on shares of Immix Biopharma from $12.00 to $15.00 and gave the company a "buy" rating in a report on Friday. Weiss Ratings restated a "sell (d-)" rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Wall Street Zen cut shares of Immix Biopharma from a "hold" rating to a "sell" rating in a report on Sunday, March 15th. Morgan Stanley assumed coverage on shares of Immix Biopharma in a research report on Wednesday. They issued an "overweight" rating and a $20.00 price objective for the company. Finally, Mizuho started coverage on shares of Immix Biopharma in a research note on Monday, February 9th. They issued an "outperform" rating and a $14.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Immix Biopharma Price Performance

IMMX opened at $8.98 on Friday. The company has a market capitalization of $475.58 million, a price-to-earnings ratio of -10.09 and a beta of 0.25. The firm's fifty day moving average price is $7.70 and its two-hundred day moving average price is $5.20. Immix Biopharma has a 1 year low of $1.34 and a 1 year high of $11.61.

Institutional Investors Weigh In On Immix Biopharma

Several large investors have recently made changes to their positions in the business. Allworth Financial LP purchased a new position in shares of Immix Biopharma in the 4th quarter worth about $30,000. Velan Capital Investment Management LP bought a new position in Immix Biopharma during the second quarter valued at about $52,000. Mathes Company Inc. purchased a new stake in Immix Biopharma during the fourth quarter worth about $56,000. Balyasny Asset Management L.P. purchased a new stake in Immix Biopharma during the fourth quarter worth about $67,000. Finally, Kera Capital Partners Inc. bought a new stake in Immix Biopharma in the fourth quarter worth about $68,000. 11.26% of the stock is owned by hedge funds and other institutional investors.

Immix Biopharma Company Profile

Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.